Jiangsu Recbio Technology Co., Ltd.
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 … Read more
Market Cap & Net Worth: Jiangsu Recbio Technology Co., Ltd. (G93)
Jiangsu Recbio Technology Co., Ltd. (F:G93) has a market capitalization of $137.59 Million (€134.04 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #20761 globally and #2241 in its home market, demonstrating a -8.62% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jiangsu Recbio Technology Co., Ltd.'s stock price €0.42 by its total outstanding shares 316138689 (316.14 Million).
Jiangsu Recbio Technology Co., Ltd. Market Cap History: 2026 to 2026
Jiangsu Recbio Technology Co., Ltd.'s market capitalization history from 2026 to 2026. Data shows growth from $137.59 Million to $137.59 Million (0.00% CAGR).
Jiangsu Recbio Technology Co., Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jiangsu Recbio Technology Co., Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of G93 by Market Capitalization
Companies near Jiangsu Recbio Technology Co., Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to Jiangsu Recbio Technology Co., Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Jiangsu Recbio Technology Co., Ltd. Historical Marketcap From 2026 to 2026
Between 2026 and today, Jiangsu Recbio Technology Co., Ltd.'s market cap moved from $137.59 Million to $ 137.59 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €137.59 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Jiangsu Recbio Technology Co., Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $137.59 Million USD |
| MoneyControl | $137.59 Million USD |
| MarketWatch | $137.59 Million USD |
| marketcap.company | $137.59 Million USD |
| Reuters | $137.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.